This executive summary provides an overview of GLP-1 medications, including what they are, how they work, and how to support consumers using them
Importantly, the initiation of neoadjuvant D + CT did not compromise eligibility or tolerability for subsequent CRT and durvalumab consolidation
Major trends include the rapid growth of the obesity drug segment, the introduction of innovative products like CagriSema and oral GLP-1 agonists, and the continued dominance of North America and Europe, which together account for over 70% of the market share
A 2025 JAMA Network Open cohort study found that most patients with overweight or obesity stopped dual-labeled GLP-1 receptor agonist therapy within 1 year
Does the half-life affect how quickly side effects resolve
People with type 2 diabetes and people who are trying to lose weight find these medications useful